This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Efficacy of 17β-Estradiol on Depression: Is Estrogen Deficiency Really Necessary?

Claudio N. Soares, Hadine Joffe, Lee S. Cohen, and Osvaldo P. Almeida

Published: May 12, 2002

Article Abstract

Letter to the Editor

Sir: Ahokas and colleagues1 recently published the results of an open-label study in which 23 women who suffered from severe postpartum depression (mean ± SD Montgomery-Asberg Depression Rating Scale [MADRS] total score = 40.7 ± 2.8; range, 35-45) received micronized 17β-estradiol (E2) sublingually for 8 weeks. The results were impressive: 39% of subjects experienced full remission of depression (MADRS total score ≤ 7) after 1 week of treatment, and almost 83% experienced full remission after 2 weeks. Two patients sustained antidepressant benefit at 4 weeks following treatment discontinuation. At baseline, 16 of 23 subjects were hypogonadal (serum E2 level < 110 pmol/L), and all subjects had a serum E2 level < 200 pmol/L.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...